Second-trimester diagnosis of most open neural tube defects has become clinically feasible in the past five years. Alpha fetoprotein is the common denominator in a two-stage screening program. Maternal serum analysis identifies high-risk pregnancies; amniotic fluid analysis is diagnostic. The biochemical basis for these tests and findings of clinical studies are reviewed.